Marine Life Preservation System using Hydrocortisone Sodium Phosphate and Monothioglycerol Formulation

Publication ID: 24-11857555_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Marine Life Preservation System using Hydrocortisone Sodium Phosphate and Monothioglycerol Formulation,” Published Technical Disclosure No. 24-11857555_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857555_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,555.

Summary of the Inventive Concept

A novel application of an aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol to mitigate the effects of climate change on marine ecosystems, preserve fish populations, and enhance seaweed growth.

Background and Problem Solved

The original patent disclosed an aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol for human use. However, the impact of climate change on marine ecosystems, including coral bleaching, aquatic plant pollution, and declining fish populations, necessitates innovative solutions. This new inventive concept addresses these pressing environmental concerns by adapting the core technology to marine life preservation.

Detailed Description of the Inventive Concept

The inventive concept comprises a system for treating marine life, a method for mitigating the effects of climate change on aquatic ecosystems, a composition for protecting aquatic plants from pollution, a system for preserving fish populations, and a method for enhancing the growth of seaweed. These applications leverage the unique properties of the hydrocortisone sodium phosphate and monothioglycerol formulation to reduce coral bleaching, promote healthy aquatic plant growth, and support thriving fish populations.

Novelty and Inventive Step

The new claims introduce a paradigm shift in the application of the original formulation, transitioning from human use to marine life preservation. This inventive step lies in the unexpected adaptation of the core technology to address the distinct challenges faced by marine ecosystems, thereby providing a novel solution to a pressing environmental problem.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include varying concentrations of hydrocortisone sodium phosphate and monothioglycerol, different administration methods, or combination therapies with other marine life preservation agents. Additionally, the formulation could be adapted for use in freshwater ecosystems or terrestrial environments.

Potential Commercial Applications and Market

The marine life preservation system has significant commercial potential in the environmental conservation and sustainability industries. Target markets include marine conservation organizations, aquaculture companies, and governments seeking to mitigate the effects of climate change on their coastal ecosystems.

Field of Art

Pharmaceutical formulations and marine biotechnology, with expertise in chemical composition, drug delivery systems, and environmental preservation techniques

Person of Ordinary Skill (PHOSITA) Profile

A professional with advanced degrees in pharmaceutical chemistry, marine biology, or biotechnology, possessing knowledge of drug formulation, chemical interactions, and ecosystem management strategies

Obviousness Rationale

A PHOSITA would recognize that the marine life preservation applications represent a straightforward extension of the original pharmaceutical formulation's core chemical properties. The hydrocortisone sodium phosphate and monothioglycerol composition demonstrates inherent protective and stabilizing characteristics that could be predictably applied to biological systems beyond human medical use. The technical principles of cellular protection and stress mitigation are fundamentally transferable across different biological contexts, making the marine ecosystem application an obvious variation of the original pharmaceutical technology.

Obvious Combinations & Variations

Source Patent Element
Aqueous pharmaceutical formulation with specific concentrations of hydrocortisone sodium phosphate and monothioglycerol
PTD Variation
Application of the same chemical formulation to marine ecosystem preservation
Obviousness Reasoning
Known chemical compounds often have broad applicability across biological systems, and the protective properties of the formulation would be predictable to a skilled practitioner
Source Patent Element
Precise concentration ranges of chemical components
PTD Variation
Adapting concentration ranges for marine life treatment
Obviousness Reasoning
Routine optimization of chemical formulations for different biological contexts represents a standard design approach in pharmaceutical and biotechnological research
Source Patent Element
Anti-inflammatory and protective pharmaceutical composition
PTD Variation
Using the formulation to mitigate environmental stress in marine ecosystems
Obviousness Reasoning
The underlying mechanism of cellular protection is fundamentally consistent across different biological systems, making cross-domain application an obvious technical extension
Source Patent Element
Stabilizing chemical interactions in pharmaceutical context
PTD Variation
Applying stabilization principles to marine life preservation
Obviousness Reasoning
A PHOSITA would recognize the potential for translating cellular protection mechanisms from pharmaceutical to environmental applications as a predictable scientific approach
35 U.S.C. § 103 Summary: Based on US Patent 11857555, the present disclosure demonstrates that the application of hydrocortisone sodium phosphate and monothioglycerol formulations to marine ecosystem preservation represents an obvious variation to a Person Having Ordinary Skill In The Art. The technical principles of cellular protection, stress mitigation, and chemical composition transfer are readily apparent and do not constitute a non-obvious innovation, thereby rendering potential claims in this domain anticipated and obvious.

Original Patent Information

Patent NumberUS 11,857,555
TitleAqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol
Assignee(s)Antares Pharma, Inc.